Adding chemotherapy to targeted therapy improves outcomes for people with advanced EGFR-positive non-small cell lung cancer.

by Sandra Gordon

Multiple myeloma survivor Jonathan Gluck reflects on uncertainty, and the scientific progress that has kept him living with cancer for more than two decades.

by Eric Fitzsimmons

From the Editor-in-Chief

Researchers examine whether removing the fallopian tubes could help prevent ovarian cancer.

by William G. Nelson, MD, PhD

Forward Look

Two targeted therapies used together extend survival for advanced non-small cell lung cancer but come with side effects.

by Darcy Lewis

Forward Look

Real-time tumor analysis offers assurance to surgeons seeking to preserve nerves involved in erectile function.

by Carolyn Bernhardt

Forward Look

Antibody-drug conjugate improves survival in people with early-stage HER2-positive breast cancer who have residual disease.

by Susan Kreimer

Forward Look

A vaccine based on a tumor’s unique genetic mutations leads to lasting immune response in locally advanced kidney cancer.

by Christina Szalinski

Antibody-drug conjugate provides an additional treatment option for people with HER2-low breast cancer.

by Kendall K. Morgan

Survivor Profile

Aurora Lucas uses social media to highlight the unique needs of young adult cancer survivors.

by Thomas Celona

Despite receiving uniquely intensive therapies, people with blood cancers are less likely to receive palliative care than those with solid tumors.

by Cameron Walker